Mass medic on J&J COVID-19 recall under review

0

Mass medic on J&J COVID-19 recall under review



>> YOU ARE WATCHING WCVB NEWSCENTER 5 AT 5:30 PM. >> A RECALL FOR JOHNSON & JOHNSON’S COVID-19 VACCINE IS NOW UNDER FDA REVIEW. HERE TO ANSWER YOUR QUESTIONS IS DR. HELEN BOUCHER, ACTING DEAN AT TUFTS SCHOOL OF MEDICINE AND INFECTIOUS DISEASE SPECIALIST AT TUFTS MEDICAL CENTER >> J&J IS NOW SAYING THAT A SINGLE SHOT OF VACCINE MAY NOT BE SUFFICIENT TO PROTECT AMERICANS. WHAT CAN YOU TELL US ABOUT THIS REMINDER DOSE? IT INCREASES PROTECTION? HOW MUCH? >> ONCE AGAIN WE HAVE DATA FROM A PRESS RELEASE FROM THE COMPANY TODAY SUGGESTING THAT A RECALL GO TO JOHNSON & JOHNSON EIGHT WEEKS AFTER THE INITIAL DOSE IS 94% EFFECTIVE IN PREVENTING ANY SYMPTOMS OF COVID DAN 100% EFFECTIVE IN PREVENTING SERIOUS DISEASES OF COVID. THAT’S GOOD. EYTH ALSO CONSIDERED A BOOERST SIX MONTHS LATER AND SHOWED VERY HIGH ANTIBODY LEVELS OF OTPRECTION. IT LOOKS GOOD. WE ALSO HAVE DATA SHOWING AT LEAST EIGHT MONTHS OF PROTECTION AFTER A SINGLE DOSE. THIS INCLUDES AGAINST THE DELTA VARIANT. TODAY WE DON’T KNOW IF SOMEONE NEEDS A BOOSTER AND IF YES, WHO MAY NEED IT. >> LET’S TALK ABOUT BLOOD CLOTS. THIS IS THE REASON WHY. – WHY WAS A BREAK ON THE JOHNSON & JOHNSON VACCINE. THIS IS NOT THE REASON THAT MANY PEOPLE GET THIS VACCINE. THE CDC HAS ALREADY WARNED WOMEN UNDER 50 TO BE AWARE OF THE RARE RISK OF BLOOD CLOTS AFTER GETTING A J&J Shot. LET’S SAY YOU HAVE A PATIENT WHO IS A WOMAN UNDER 50, WILL YOU SAY IT IS WORTH THE RISK OF GETTING A SECOND JOHNSON & JOHNNSO STHO? >> WE DON’T KNOW BAUECSE YET WE HAVE NOT SEEN ANY FMRO DATA BOOSTING STUDIES TO LOOK AT THINGS LIKE SAFETY. TODAY WE KNOW THAT A SINGLE DOSE AS YOU MENTIONED IS SAFE AND EFFECTIVE. QUEIT THE CDC DOES NOT RECOMMEND ONE VACCINE OVER ANOTHER. – >> THE CDC DOES NOT RECOMMEND ONE VACCINE OVER ANOTHER. >> WHAT WILL BE YOUR ADVICE AND CHOICES ON WHAT THEY SHOULD DO AND WHAT THEY SHOULD GET? >> I ALWAYS RECOMMEND THAT YOU OBTAIN THE VACCINE THAT IS AVAILABLE TO YOU. TODAY WE HAVE THREE VYER SRS AND EFFECTIVE VACCINES THAT WE HAVE BEEN USED ON MILLIONS OF PEOPLE. >> THE NEW CESAS AT MASSACHUSETTS WERE DOWN 14%. YESTERDAY DOWN 20. THIS WAS THE TREND, FALLING BETWEEN 10 AND 20%. SOME PEOPLE MAY WATCH THESE DROPPING SECA NUMBERS AND THINK THAT DR. SGEUR – IS THIS DR. OVERVIEW COMPLETED? WHAT ARE YOU SAYING? >> THESE DATA ARE ENCOURAGING. IT IS WONDERFUL TO SEE A REDUCTION IN HOSPITALIZATIONS AND DEATHS. THIS VIRUS IS NOT YET ENDED. IT IS IMPORTANT THAT THOSE WHO HAVE NOT BEEN VACCINATED GET THIS VACCINE. THEY MUST GO FORWARD AND GET THIS VACCINE TO GET FULL PROTECTION. WE DON’T WANT TO ALLOW OTHER VARIANTS TO EMERGING AND WE WANT IT TO BE ANDY. >> WE APPRECIATE YOUR PREVIEW AS ALWAYS. THANK YOU SO MUCH.

Mass medic on J&J COVID-19 recall under review

Dr. Helen Boucher, an infectious disease specialist at Tufts Medical Center, explains what the recall hopes to accomplish.

Dr. Helen Boucher, an infectious disease specialist at Tufts Medical Center, explains what the recall hopes to accomplish.


Source link

Leave A Reply

Your email address will not be published.